US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
USOTC
Pola Orbis Holdings Inc (PK) (PORBF) 銘柄情報

Pola Orbis Holdings Inc (PK) (PORBF)

7.70

0.00

(0.00%)

終了 6月13日 5:00AM

Pola Orbis Holdings Inc (PK) (PORBF) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

7.70

( - )

買値

7.23

売値

8.54

出来高

-

0.00 日の範囲 0.00

7.70 52 週間の範囲 9.95

時価総額

前日終値

7.70

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 548,340

発行済株式数

221,282,069

配当利回り

52 (4.09%)

PER

26.18

1 株当たり利益 (EPS)

47.95

歳入

169.8B

純利益

10.63B

Pola Orbis Holdings Inc., through its subsidiaries, develops, manufactures, and sells cosmetics and related products in Japan, Asia, and internationally. It operates through Beauty Care, Real Estate, and Others segments. The company offers beauty and health products under the POLA, ORBIS, Jurlique, ... Pola Orbis Holdings Inc., through its subsidiaries, develops, manufactures, and sells cosmetics and related products in Japan, Asia, and internationally. It operates through Beauty Care, Real Estate, and Others segments. The company offers beauty and health products under the POLA, ORBIS, Jurlique, THREE, DECENCIA, and FUJIMI brand names. It is also involved in the leasing of office buildings in urban areas, as well as management and operation of buildings. Pola Orbis Holdings Inc. was founded in 1929 and is headquartered in Tokyo, Japan. 詳細を表示

セクター

Consumer Staples

業界

Consumer Products - Household & Personal

ウェブサイト

www.po-holdings.co.jp

本社

Tokyo, Japan

設立

2026

Pola Orbis Holdings Inc (PK) is listed in the Consumer Staples sector of the その他OTC with ticker PORBF. The last closing price for Pola Orbis (PK) was US$7.70. Over the last year, Pola Orbis (PK) shares have traded in a share price range of US$ 7.70 to US$ 9.95.

Pola Orbis (PK) currently has 221,282,069 shares in issue. The market capitalisation of Pola Orbis (PK) is US$1.70 billion. Pola Orbis (PK) has a price to earnings ratio (PE ratio) of 26.18.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	7.7	7.7	7.7	100	7.7	CS
4	0	0	7.7	7.7	7.7	100	7.7	CS
12	-1	-11.4942528736	8.7	8.7	7.7	25	7.7	CS
26	-1.4	-15.3846153846	9.1	9.1	7.7	575	8.67826087	CS
52	-2.25	-22.6130653266	9.95	9.95	7.7	438	8.8638587	CS
156	-3.35	-30.3167420814	11.05	11.05	7.7	492	9.63092756	CS
260	-19.8989	-72.1003373323	27.5989	27.5989	7.7	894	11.6058232	CS

PORBF - Frequently Asked Questions (FAQ)

What is the current Pola Orbis Holdings Inc (PK) share price?

The current share price of Pola Orbis Holdings Inc (PK) is US$ 7.70

How many Pola Orbis Holdings Inc (PK) shares are in issue?

Pola Orbis Holdings Inc (PK) has 221,282,069 shares in issue

What is the market cap of Pola Orbis Holdings Inc (PK)?

The market capitalisation of Pola Orbis Holdings Inc (PK) is USD 1.7B

What is the 1 year trading range for Pola Orbis Holdings Inc (PK) share price?

Pola Orbis Holdings Inc (PK) has traded in the range of US$ 7.70 to US$ 9.95 during the past year

What is the PE ratio of Pola Orbis Holdings Inc (PK)?

The price to earnings ratio of Pola Orbis Holdings Inc (PK) is 26.18

What is the cash to sales ratio of Pola Orbis Holdings Inc (PK)?

The cash to sales ratio of Pola Orbis Holdings Inc (PK) is 1.64

What is the registered address of Pola Orbis Holdings Inc (PK)?

The registered address for Pola Orbis Holdings Inc (PK) is 2-2-3 Nishigotanda, Tokyo, 141-0031

What is the Pola Orbis Holdings Inc (PK) website address?

The website address for Pola Orbis Holdings Inc (PK) is www.po-holdings.co.jp

Which industry sector does Pola Orbis Holdings Inc (PK) operate in?

Pola Orbis Holdings Inc (PK) operates in the Consumer Products - Household & Personal sector

81vette

81vette 9分前

I understand now,merger had a 20 day mandatory waiting period,it ended and merger was complete and new company’s first day was Thursday,Friday was 1st day of some institutional buying (burst basket trades) Monday could be really good ,I bet updates/PRs will be often now.
We made it thru the

RockQQ

RockQQ 10分前

Wow, we always suspected! Good link!

RockQQ

midastouch017

midastouch017 12分前

I came to the sad conclusion that discussing
RDHL is a sheer waste of time!
:-(

MartinLutherKing

MartinLutherKing 12分前

The short song and dance is over rockafella, You just can’t get em cheapies so easily.. You got to pay to play in the big leagues

janice shell

janice shell 22分前

Oh yes, I remember. It's a pretty color. And they're very useful.

I may not be able to resist. It really IS a fabulous value. The reviewers seem to like it.

surfer44

surfer44 22分前

2026 10th Capital Link Maritime Leaders Summit – Greece | Dry Bulk at an Inflection Point

https://youtu.be/adh3JnRr8qo

Whalatane

Whalatane 27分前

My debate with Claude
Velphoro leaves 100% TDAPA reimbursement Dec 31st 2026 . OLC if approved starts 100% reimbursement ...so won't Fresenius want to switch patients to OLC especially if licensed by CSL Vifor9:44 PM

????Claude responded:
That changes the calculus mean

shajandr

shajandr 27分前

I bought this one in 2025 and am pleased with it so far.

https://investorshub.advfn.com/uimage/uploads/2026/6/13/xfifamueller.JPG

https://www.amazon.com/dp/B0DRDNZDHK?ref=ppx_yo2ov_dt_b_fed_asin_title&th=1

BTW, when I put the bunnies' food ~OUTT under the

jour_trader

jour_trader 30分前

lol there was no waiver. Glad you are now caught up on the real timeline.

wadegarret

wadegarret 34分前

Valuemind- SNDK

Are you not concerned that despite only a 11-12 PE going forward, that this is a highly cyclical stock up from $30 a year ago ? I mean in other words, if judging the value of a stock today is based on future earnings going out at least 2-3 years, how can one have

Whalatane

Whalatane 36分前

Searched the webHere's the mechanism if OLC (Renazorb) gets FDA approval and TDAPA designation:...via Claude

Normal economics without TDAPA:
Phosphate binders fall inside Medicare's ESRD bundled payment (~$281.71/treatment). Any drug a clinic uses comes out of that fixed bund

mmayr

Complete Meltdown is Coming

https://youtu.be/5sp1minxEns?is=-W1we0evirBu6yX9

boston127

boston127 44分前

Something good is happening here.

I'm not dumping, just trying to sell high and buy low.

shajandr

shajandr 44分前

As you've nott replied to my questions (perhaps you, like many/most others have me on Ignore), infra, prolly in view of there being no meritorious argument supporting the SEC's so-kalt 'gag rule' on settlements, I've restructured my inquiry. I'd still enjoy reading your reply to the original questio

janice shell

janice shell 45分前

I'll bet you can even get ivermectin at Amazon now. You can get everything at Amazon.

Damn, should I get this? It's tempting. Fantastic price:

https://investorshub.advfn.com/uimage/uploads/2026/6/13/vujmmimage.jpeg

https://www.amazon.com/EDGING-CASTING-En

bim524

bim524 46分前

Maybe you should go to an Amazon board and complain over there Instead of spreading this nonsense about a fake agreement here. If you even had any semblance of historical fact you would pretend to know that this company won’t even name companies in their PRs… if they issue a statement that says ther

Just give me $1.50

Just give me $1.50 46分前

Huh?

You haven't been watching and/or listening to the news?

Because of peace talks failing, and the War in Iran restarting, Elite submitted a waiver request to the SEC to have their 10-K filing deadline pushed back by two weeks due to safety concerns.

It

HyGro

No biotech passes on the chance for an FDA approval -- NWBO sure did and likely because FDA told them not to bother. No oncology drug can be very profitable with out U.S. approval. NWBO didn't even try. Why, because they knew they wouldn't get accepted. Just watch, NWBO won't apply for FDA

grantastic

grantastic 49分前

It is crazy to believe that HDUP is pursuing any legitimate business deals.

Especially after Mark Hutchison scrubbed all mention of HDUP from his professional profile. He's moved on from the scam. Shareholders need to move on too.

The only evidence ever shown of these

sandor8

sandor8 49分前

It is only proving to itself to be part of the group of psychopath an sociopath world over known today, only needing a driver of a tank to hint physically to them that our essence can be flattened, quite simplifying and ameliorating the other's existence.

normal investor

normal investor 52分前

Just give me $1.50

Just give me $1.50 53分前

LMAO.

1-2 years?

You mean 1-2 ............. WEEKS?

Shareholder: "Is the timeline for uplisting to NASDAQ or acquisition merger still on track to be around August 2026?"

Nasrat: "NO!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!"

nowwhat2

nowwhat2 58分前

https://investorshub.advfn.com/uimage/uploads/2026/6/13/kgwzibtc_june_12_zoom_cup_depend.jpghttps://investorshub.advfn.com/uimage/uploads/2026/6/13/wvapvdepend_sikh.jpg

.

mrwrn2010

mrwrn2010 1時間前

What I’m reading seems to indicate that Elite is still not prevented from obtaining *tentative approval* from the FDA on the OxyContin ANDA, only that they can’t get final approval until/after 8/24/27. I believe Nasrat also confirmed this last call. Ideally, we see a tentative Oxy approval sometime

Pola Orbis (PK)

Karamolengos Bakery Indu...

DAXsector All Retail Per...

VictoryShares Internatio...

Pediatrix Medical

Graphique INAV 025 Dummy...

Resimac Bastille Trust S...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。